Company Filing History:
Years Active: 2000-2003
Title: Albert Paul Reed: Innovator in Veterinary Medicine
Introduction
Albert Paul Reed is a notable inventor based in Exton, PA (US). He has made significant contributions to the field of veterinary medicine, particularly in the area of coronaviruses affecting felines and canines. With a total of 5 patents to his name, Reed's work has been instrumental in advancing diagnostic and therapeutic methods for these diseases.
Latest Patents
Reed's latest patents include groundbreaking inventions such as the "Recombinant feline coronavirus S proteins." This invention relates to polypeptides and proteins that are useful in the diagnosis and prevention of diseases caused by feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FECV). Another significant patent is the "Canine coronavirus S gene and uses therefor," which provides the amino acid and nucleotide sequences of a CCV spike gene. This invention includes compositions containing one or more fragments of the spike gene and encoded polypeptide for prophylaxis, diagnostic purposes, and treatment of CCV infections.
Career Highlights
Albert Paul Reed is currently associated with Pfizer Corporation, a leading pharmaceutical company. His work at Pfizer has allowed him to collaborate with other experts in the field, enhancing the impact of his inventions on veterinary health.
Collaborations
Some of Reed's notable coworkers include Timothy J. Miller and Sharon R. Klepfer. Their collaborative efforts have contributed to the development of innovative solutions in veterinary medicine.
Conclusion
Albert Paul Reed's contributions to veterinary medicine through his patents and collaborations highlight his commitment to improving animal health. His work continues to pave the way for advancements in the diagnosis and treatment of coronavirus infections in pets.